Heron Therapeutics
HRTX
199 hedge funds and large institutions have $2.27B invested in Heron Therapeutics in 2019 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 78 increasing their positions, 51 reducing their positions, and 12 closing their positions.
456% more call options, than puts
Call options by funds: $45.6M | Put options by funds: $8.19M
200% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 12
53% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 51
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
13% more funds holding
Funds holding: 176 → 199 (+23)
1.76% more ownership
Funds ownership: 117.09% → 118.84% (+1.8%)
4% less capital invested
Capital invested by funds: $2.37B → $2.27B (-$97.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$34.6M |
| 2 |
JP Morgan Chase
New York
|
+$17.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.8M |
| 4 |
WM
WS Management
Jacksonville,
Florida
|
+$12M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$44.3M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$33.7M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$12.7M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$12.6M |
| 5 |
BM
Bridger Management
New York
|
-$11.7M |
HRTX Hedge Fund Activity: Q1 2019 in Review
199 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2019, worth a combined $2.27B — down 4.1% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new HRTX positions and 12 closed out — a net gain of 24 holders — while 78 added to existing stakes and 51 trimmed.
The largest buyer was ClearBridge Investments, adding an estimated $34.6M. The largest seller was Citadel Advisors, cutting an estimated $44.3M.
- 199 institutional investors held Heron Therapeutics (HRTX) as of Q1 2019, up from 176 in Q4 2018.
- Funds reported $2.27B of Heron Therapeutics stock for Q1 2019, down 4.1% quarter-over-quarter.
- 36 funds opened new Heron Therapeutics positions in Q1 2019 and 12 closed out, a net change of +24 holders.
- The largest Heron Therapeutics buyer in Q1 2019 was ClearBridge Investments, an estimated $34.6M added.
- The largest Heron Therapeutics seller in Q1 2019 was Citadel Advisors, an estimated $44.3M sold.
Based on aggregated 13F filings for Q1 2019.